Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pietro Invernizzi

Showing results (401-410 of 420) with videos related to

Pageof 42
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2024
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of CholestasisVincenza Calvaruso, Ciro Celsa, Laura Cristoferi, et al.
Journal of Hepatology|July 1, 2022
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitisChristophe Corpechot, Fabrice Carrat, Farid Gaouar, et al.
JHEP Reports : Innovation in Hepatology|October 9, 2024
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitisSurain B Roberts, Woo Jin Choi, Lawrence Worobetz, et al.
Frontiers in Medicine|January 11, 2021
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational StudyStefano Partelli, John K Ramage, Sara Massironi, et al.
The British Journal of Surgery|August 20, 2022
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trialStefano Partelli, Sara Massironi, Alessandro Zerbi, et al.
Hepatology (Baltimore, Md.)|July 3, 2023
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?Christophe Corpechot, Sara Lemoinne, Pierre-Antoine Soret, et al.
Journal of Hepatology|October 5, 2025
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitisYu Jun Wong, Laurent Lam, Pierre-Antoine Soret, et al.
JHEP Reports : Innovation in Hepatology|March 8, 2021
Real-world experience with obeticholic acid in patients with primary biliary cholangitisDaphne D'Amato, Antonio De Vincentis, Federica Malinverno, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 17, 2024
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary CholangitisLaurent Lam, Pierre-Antoine Soret, Sara Lemoinne, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 6, 2022
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acidAntonio De Vincentis, Daphne D'Amato, Laura Cristoferi, et al.
Pageof 42

Showing results (401-410 of 420) with videos related to

Sort By:
Pageof 42
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2024
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of CholestasisVincenza Calvaruso, Ciro Celsa, Laura Cristoferi, et al.
Journal of Hepatology|July 1, 2022
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitisChristophe Corpechot, Fabrice Carrat, Farid Gaouar, et al.
JHEP Reports : Innovation in Hepatology|October 9, 2024
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitisSurain B Roberts, Woo Jin Choi, Lawrence Worobetz, et al.
Frontiers in Medicine|January 11, 2021
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational StudyStefano Partelli, John K Ramage, Sara Massironi, et al.
The British Journal of Surgery|August 20, 2022
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trialStefano Partelli, Sara Massironi, Alessandro Zerbi, et al.
Hepatology (Baltimore, Md.)|July 3, 2023
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?Christophe Corpechot, Sara Lemoinne, Pierre-Antoine Soret, et al.
Journal of Hepatology|October 5, 2025
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitisYu Jun Wong, Laurent Lam, Pierre-Antoine Soret, et al.
JHEP Reports : Innovation in Hepatology|March 8, 2021
Real-world experience with obeticholic acid in patients with primary biliary cholangitisDaphne D'Amato, Antonio De Vincentis, Federica Malinverno, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 17, 2024
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary CholangitisLaurent Lam, Pierre-Antoine Soret, Sara Lemoinne, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 6, 2022
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acidAntonio De Vincentis, Daphne D'Amato, Laura Cristoferi, et al.
Pageof 42